Stabilized formulation of affimer and method for preparing same

The stabilization formulation for fusion proteins using anionic stabilizers addresses the stability challenges faced by protein drugs, ensuring prolonged stability and activity, thereby enhancing therapeutic efficacy.

WO2025084804A1PCT designated stage expired Publication Date: 2025-04-24LG CHEM LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/015755
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-18
Filing Date
2024-10-17
Publication Date
2025-04-24

AI Technical Summary

Technical Problem

Protein drugs, including fusion proteins targeting PD-L1, face challenges in stability due to factors like temperature, shear stress, and chemical exposure, leading to denaturation and reduced efficacy.

Method used

A stabilization formulation for fusion proteins using a stabilizer that provides an anion, such as sulfate, malate, or tartrate, is developed to maintain protein activity and stability over time.

Benefits of technology

The use of anionic stabilizers effectively prolongs the stability and activity of fusion proteins, enhancing their therapeutic potential by reducing degradation and maintaining efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a stabilized formulation of a fusion protein, which includes a stabilizing agent composed of a material that provides at least one type of anion selected from the group consisting of sulfate, malate, and tartrate, wherein the stabilizing agent allows the fusion protein to be stably stored for a long period of time.
Need to check novelty before this filing date? Find Prior Art

Description

Stabilized formulation of AFFIMER and method for producing the same

[0001] The present invention relates to a stabilizing formulation of a fusion protein comprising a stabilizer comprising a substance providing an anion.

[0002]

[0003] The programmed cell death-1 (PD-1) receptor is expressed on the surface of activated T cells. The ligands PD-L1 and PD-L2 are expressed on the surface of dendritic cells or macrophages. PD-1 and PD-L1 / PD-L2 belong to a family of immune checkpoint proteins that act as corepressors that can halt or limit the development of T cell responses. The PD-1 / PD-L1 interaction ensures that the immune system is activated only at the appropriate time to minimize the potential for chronic autoimmune inflammation. The PD-1 / PD-L1 pathway represents an adaptive immune resistance mechanism used by tumor cells in response to intrinsic immune antitumor activity. PD-L1 is overexpressed on tumor cells or non-transformed cells in the tumor microenvironment. PD-L1 expressed on tumor cells binds to the PD-1 receptor on activated T cells, suppressing cytotoxic T cells. These anergized and exhausted T cells remain suppressed in the tumor microenvironment.

[0004]

[0005] In general, protein pharmaceuticals have very short half-lives of their active ingredients and are easily chemically and physically denatured by factors such as unsuitable temperatures, shear stress, vibration, freeze-thawing, UV exposure, excessive pH changes, organic solvents, and microbial contamination. Various methods have been studied to prevent protein denaturation in solution, and some protein pharmaceuticals have solved the stability issue by using lyophilization. However, to manufacture a stabilized formulation of these drugs, an appropriate stabilizer must be used according to the physicochemical properties of each active ingredient. Combining stabilizers can lead to adverse effects, which are different from the intended effect, due to competition and side effects.

[0006]

[0007] The present inventors studied a method for preparing a solution formulation capable of stably maintaining the activity of a fusion protein binding to PD-L1, and discovered that a stabilizer composed of a substance providing anions is remarkably effective in stabilizing the fusion protein of the present invention, thereby completing the present invention.

[0008]

[0009] One object of the present invention is to provide a stabilizing formulation of a fusion protein comprising a stabilizer comprising a substance providing an anion.

[0010]

[0011] By using a stabilizer comprising an anion-providing material of the present invention, the fusion protein of the present invention can be stably preserved for a long period of time. Therefore, the stabilizing agent of the present invention can be effectively applied in therapeutic fields related to the pharmacological efficacy of the fusion protein of the present invention.

[0012]

[0013] Hereinafter, the present invention will be described in more detail.

[0014]

[0015] Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention is not limited by the specific descriptions described below.

[0016] Furthermore, those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments of the invention described herein. Furthermore, such equivalents are intended to be encompassed by the present invention.

[0017]

[0018] One aspect of the present invention provides a stabilizing formulation of a fusion protein comprising a stabilizer comprising a material providing an anion.

[0019] As one specific example, the stabilizing agent is characterized as a stabilizing agent of a fusion protein comprising a structure represented by the following general formula 1:

[0020] [General Formula 1]

[0021] Q1-L-Q2-L-Q3

[0022] However, the above Q1 and Q2 include a polynucleotide encoding a PD-L1 binding polypeptide, and Q3 includes a polynucleotide encoding an HSA binding polypeptide,

[0023] L represents a linker containing A(EAAAK)n as a repeating unit,

[0024] The above n is an integer from 3 to 10.

[0025] A stabilizing agent according to any one of the preceding specific examples, characterized in that the substance providing the anion is at least one selected from the group consisting of sulfate, malate, and tartrate.

[0026] A stabilizing agent according to any one of the preceding specific examples, wherein the anion-providing material is characterized in that at least one selected from the group consisting of ammonium sulfate, potassium sulfate, sodium sulfate, calcium sulfate, magnesium sulfate, malic acid, ammonium malate, sodium malate, calcium malate, potassium malate, magnesium malate, tartaric acid, ammonium tartrate, sodium tartrate, calcium tartrate, potassium tartrate, and magnesium tartrate.

[0027] A stabilizing agent according to any one of the preceding specific examples, characterized in that the stabilizer is present at a concentration of 0.1 mM to 800 mM.

[0028] A stabilizing agent according to any one of the preceding specific examples, wherein the stabilizing agent is characterized in that the storage stability is increased compared to a formulation to which a stabilizing agent is added, excluding a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate.

[0029] A stabilizing agent according to any one of the preceding specific examples, characterized in that the stabilizing agent further comprises a surfactant.

[0030] A stabilizing agent according to any one of the preceding specific examples, wherein the surfactant is a nonionic surfactant.

[0031] A stabilizing agent according to any one of the preceding specific examples, wherein the surfactant is polysorbate 80, polysorbate 20, or poloxamer 188.

[0032] A stabilizing agent according to any one of the preceding specific examples, characterized in that the surfactant in the stabilizing agent is present in a concentration of 0.1 to 2 wt%.

[0033] A stabilizing agent according to any one of the preceding specific examples, characterized in that the fusion protein is present at a concentration of 1 to 30 mg / ml.

[0034] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q1 and Q2 is characterized in that it has at least 90% identity with the sequence represented by SEQ ID NO: 1.

[0035] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q1 is characterized by consisting of an amino acid of SEQ ID NO: 2 or SEQ ID NO: 3.

[0036] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q2 is characterized in that it consists of an amino acid of SEQ ID NO: 1.

[0037] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q3 is characterized in that it has at least 90% identity with the sequence represented by SEQ ID NO: 4.

[0038] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q3 is characterized in that it consists of an amino acid of SEQ ID NO: 4.

[0039] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q1 is characterized by consisting of an amino acid of SEQ ID NO: 2 or SEQ ID NO: 3.

[0040] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q2 is characterized in that it consists of an amino acid of SEQ ID NO: 1.

[0041] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q3 is characterized in that it has at least 90% identity with the sequence represented by SEQ ID NO: 4.

[0042] A stabilizing agent according to any one of the preceding specific examples, wherein the polypeptide encoded by Q3 is characterized in that it consists of an amino acid of SEQ ID NO: 4.

[0043] A stabilizing agent according to any one of the preceding specific examples, wherein the fusion protein is characterized by being composed of amino acids of SEQ ID NO: 5 or SEQ ID NO: 6.

[0044]

[0045] The present invention will now be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention.

[0046]

[0047] One embodiment of the present invention is a stabilizing formulation of a fusion protein comprising a stabilizer comprising a substance providing an anion.

[0048] The term "stabilizer" as used herein refers to a specific chemical compound that interacts with and stabilizes biological molecules and / or common pharmaceutical excipients in a formulation. Stabilizers generally protect proteins from air / solution interface-induced stress and solution / surface-induced stress, which can lead to protein aggregation. In the present invention, the stabilizer refers to a component that reduces the formation of byproducts of the fusion protein during storage in a solution state, thereby maintaining its activity for a long period of time. In one embodiment, the stabilizing formulation of a fusion protein may include a stabilizer comprising a substance that provides one or more anions selected from the group consisting of sulfate, malate, and tartrate.

[0049] In one embodiment, the material providing the anion may be at least one selected from the group consisting of ammonium sulfate, potassium sulfate, sodium sulfate, calcium sulfate, magnesium sulfate, malic acid, ammonium malate, sodium malate, calcium malate, potassium malate, magnesium malate, tartaric acid, ammonium tartrate, sodium tartrate, calcium tartrate, potassium tartrate, and magnesium tartrate.

[0050] In addition, the stabilizing agent may be characterized by increased storage stability compared to a formulation to which a stabilizing agent is added, excluding a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate.

[0051] In one embodiment, the stabilizer, excluding a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate, may be any substance excluding sulfate, malate, and / or tartrate, but is not limited thereto. In addition, the stabilizer of the present invention, which is composed of a substance providing at least one anion selected from the group consisting of sulfate, malate, and tartrate, may further include at least one substance selected from the group consisting of sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium phosphate, sodium acetate, sodium succinate, beta-cyclodextrin (Beta-CD), amino acid, polyethylene glycol (PEG), hyaluronic acid (HA), chondroitin sulfate C (CS-C), maleic acid, and propylene glycol, but is not limited thereto.

[0052] The stabilizer may be present at a concentration of about 0.01 mM to 1000 mM. Specifically, the stabilizer may be present at a concentration of about 0.1 mM to 1000 mM, a concentration of about 0.01 mM to 900 mM, a concentration of about 0.1 mM to 800 mM, a concentration of about 1.0 mM to 1000 mM, a concentration of about 1.0 mM to 900 mM, a concentration of about 1.0 mM to 800 mM, a concentration of about 5.0 mM to 1000 mM, a concentration of about 5.0 mM to 900 mM, a concentration of about 5.0 mM to 800 mM, or a concentration of about 10 mM to 800 mM, but is not limited thereto.

[0053]

[0054] As confirmed in one embodiment of the present invention, when a substance other than sulfate, malate, and tartrate, which are substances providing anions of the present invention, were added, it was confirmed that the stability of the fusion protein according to the present invention increased based on a similar osmotic pressure.

[0055] Meanwhile, in the case of high-concentration protein pharmaceuticals, pain may be induced if the osmotic pressure of the solution deviates from the osmotic pressure range similar to that of body fluids. For example, if the osmotic pressure is too low, hemolysis of red blood cells may occur when injected into a blood vessel, and if the osmotic pressure is too high, pain may be induced and blood vessels may be damaged. The most appropriate osmotic pressure for in vivo administration is an isotonic solution similar to blood (250-350 mOsm / kg). However, in the case of intravenous injection products, they are diluted in isotonic solutions such as saline or glucose, so the osmotic pressure of the drug itself may be high. If the stability is better at the same osmotic pressure, the dilution ratio in saline can be reduced, which has the advantage of reducing the total injection amount.

[0056]

[0057] In one embodiment, the stabilizing formulation may further comprise a surfactant. Specifically, the surfactant included in the stabilizing formulation of the present invention may be a nonionic surfactant. More specifically, the surfactant may be a polysorbate or a poloxamer.

[0058] Additionally, the surfactant may be, but is not particularly limited to, polysorbate 80, polysorbate 20, or poloxamer 188.

[0059] In the above stabilizing formulation, the surfactant may be present at a concentration of about 0.01 to 5 wt%. Specifically, the surfactant may be present at a concentration of about 0.01 to 5 wt%, about 0.1 to 5 wt%, about 0.01 to 4 wt%, about 0.1 to 4 wt%, about 0.01 to 3 wt%, about 0.1 to 3 wt%, about 0.01 to 2 wt%, or about 0.1 to 2 wt%, but is not limited thereto.

[0060]

[0061] Additionally, the fusion protein may comprise a structure represented by the following general formula 1:

[0062] [General Formula 1]

[0063] Q1-L-Q2-L-Q3

[0064] However, the above Q1 and Q2 include a polynucleotide encoding a PD-L1 binding polypeptide, and Q3 includes a polynucleotide encoding an HSA binding polypeptide,

[0065] L represents a linker containing A(EAAAK)n as a repeating unit,

[0066] The above n is an integer from 3 to 10.

[0067]

[0068] In one embodiment, the “fusion protein” of the present invention refers to a fusion protein expressed by an expression construct capable of expressing a PD-L1 / HSA binding polypeptide peptide. As used herein, the fusion protein may be referred to interchangeably as “XT 35” or “PD-L1 / XT Affimer®.”

[0069] As used herein, the term "AFFIMER® polypeptide" (also referred to as "AFFIMER® protein") refers to a small, highly stable protein that is an engineered variant of the Stefin polypeptide.

[0070] The above stephin polypeptides belong to a subgroup of proteins in the cystatin superfamily, a family of proteins containing multiple cystatin-like sequences. The stephin subgroup of the cystatin family comprises relatively small (approximately 100 amino acids) single-domain proteins. They are not subject to post-translational modifications and lack disulfide bonds, suggesting that they can fold identically in a wide range of extracellular and intracellular environments. Stephin A itself is a single-chain, single-domain protein consisting of 98 amino acids. Stephin A promotes mutations with AFFIMER® polypeptides. The only known biological activity of cystatins is inhibition of cathepsin activity.

[0071] The AFFIMER® protein displays two peptide loops and an N-terminal sequence that can be randomized to bind to a desired target protein with high affinity and specificity, similar to a monoclonal antibody. Stabilization of the two peptides by the stefin A protein scaffold restricts the possible conformations the peptides can adopt, thereby increasing binding affinity and specificity compared to a free peptide library. These engineered, non-antibody-binding proteins are designed to mimic the molecular recognition properties of monoclonal antibodies in a variety of applications. Furthermore, modifications to other portions of the stefin A polypeptide sequence can be made, which improve the properties of the affinity reagent, such as increased stability, making it robust across a range of temperatures and pHs. The AFFIMER® polypeptide comprises a sequence derived from stefin A that shares substantial identity with the wild-type stefin A sequence, such as human stefin A. It will be apparent to those skilled in the art that modifications to the scaffold sequence can be made without departing from the teachings disclosed herein. In particular, the AFFIMER® polypeptide can have an amino acid sequence that is at least 25%, 35%, 45%, 55%, or 60% identical to a sequence corresponding to human stefin A. For example, at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, or at least 95% identical, provided that the sequence variation does not adversely affect the ability of the scaffold to bind to a desired target (e.g., PD-L1), and does not restore or create a biological function, such as a function possessed by wild-type stefin A but abolished by a mutational change described herein.

[0072] As used herein, the term "AFFIMER® linked conjugate" means an AFFIMER® formulation having at least one moiety linked thereto by a chemical bond other than through the formation of a contiguous peptide bond via the C-terminus or N-terminus of a polypeptide portion of the AFFIMER® formulation containing an AFFIMER® polypeptide sequence. An AFFIMER® linked conjugate may be an "AFFIMER® polypeptide-drug conjugate," which means an AFFIMER® formulation comprising at least one pharmacologically active moiety linked thereto. An AFFIMER® linked conjugate may also be an "AFFIMER® tag conjugate," which means an AFFIMER® formulation comprising at least one detectable moiety (e.g., a detectable label) linked thereto.

[0073] In the present invention, the term “human serum albumin (HSA)” refers to a protein encoded by the ALB gene. HSA is a 585 amino acid polypeptide (approximately 67 kDa) with a serum half-life of about 20 days and is primarily responsible for colloid osmotic pressure, maintenance of blood pH, and transport and distribution of numerous endogenous and exogenous ligands. HSA has three structurally homologous domains (domains I, II, and III), is almost entirely in an alpha-helical conformation, and is highly stabilized by 17 disulfide bridges. A representative HSA sequence is provided by UniProtKB Primary Accession Number P02768 and may include other human isoforms thereof. “HSA AFFIMER® formulation” means a preparation comprising at least 10 -6MRefers to an AFFIMER® formulation comprising at least one AFFIMER® polypeptide that binds to serum albumin, particularly human serum albumin, with a dissociation constant (Kd). As used herein, the term 'PD-L1 (Programmed Cell Death Ligand 1)' plays an important role in suppressing immune responses and promoting self-tolerance by regulating the activity of T cells, activating apoptosis of antigen-specific T cells, and inhibiting apoptosis of regulatory T cells. PD-L1 is a transmembrane protein considered a corepressor of the immune response, and binds to PD-1 to reduce the proliferation of PD-1 positive cells and induce cytokine secretion and apoptosis. It also plays an important role in various malignancies that can weaken the host immune response to tumor cells.

[0074] PD-L1 is commonly expressed by macrophages, some activated T and B cells, dendritic cells (DCs), and some epithelial cells, particularly in inflammatory diseases. PD-L1 acts as an oncogenic factor in cancer cells by binding to its receptor and activating proliferation and survival signaling pathways.

[0075]

[0076] Specifically, the polynucleotide encoding the PD-L1 binding polypeptide in the general formula 1, i.e., the polypeptide encoded by Q1 and Q2, may have 90% or more homology or identity with the sequence represented by SEQ ID NO: 1, but is not limited thereto.

[0077] In one embodiment, the PD-L1 binding polypeptide of the present invention may be a sequence comprising, consisting essentially of, or consisting of a polypeptide sequence of SEQ ID NO: 1. For example, the PD-L1 binding polypeptide may be a polypeptide sequence having at least 70%, for example, at least 80%, 90%, 95%, 96%, 97%, 98%, 99% sequence homology or identity with the polypeptide sequence of SEQ ID NO: 1, but is not limited thereto, and any sequence having the same activity as a polynucleotide encoding the polypeptide sequence of SEQ ID NO: 1 may be included without limitation.

[0078] As used herein, the terms "homology" or "identity" refer to the degree of relationship between two given amino acid sequences or base sequences, and may be expressed as a percentage. The terms "homology" and "identity" are often used interchangeably.

[0079] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences are generally capable of hybridizing under moderate or high stringency conditions, typically along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its entire length. It should be appreciated that hybridization also encompasses polynucleotides containing common codons or codons that are considered codon degenerate.

[0080] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA / .](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database.

[0081] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a binary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and (2) a comparison matrix as disclosed by Gribskov et al. (1986) Nucl. Acids Res. 48:443, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979). 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.

[0082] Additionally, whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and appropriate hybridization conditions are within the skill of the art and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York).

[0083]

[0084] Specifically, the PD-L1 binding polypeptide of Q1 may have alanine (Ala) or glycine (Gly) inserted between the N-terminal first amino acid, methionine (Met), and the second amino acid. For example, the N-terminal sequence of the PD-L1 binding polypeptide of Q1 may be a MAIP or MGIP sequence, and the polypeptide encoded by Q1 may be composed of amino acids of SEQ ID NO: 2 or SEQ ID NO: 3, but is not limited thereto.

[0085]

[0086] In addition, the above Q2 is characterized in that alanine (Ala) or glycine (Gly) is not inserted between the first amino acid methionine (Met) and the second amino acid at the N-terminus of the PD-L1 binding polypeptide, and the polypeptide encoded by the above Q2 may be composed of amino acids of sequence number 1, but is not limited thereto.

[0087]

[0088] In one embodiment, the polynucleotide encoding the HSA binding polypeptide included in the expression cassette, i.e., the polypeptide encoded by Q3, may have at least 90% identity with the sequence represented by SEQ ID NO: 4, and specifically, the polypeptide encoded by Q3 may be composed of amino acids of SEQ ID NO: 4, but is not limited thereto.

[0089]

[0090] In one embodiment, Q1, Q2 and Q3 of the expression cassette may each be connected via a linker (L), and L may include EAAAK as a repeating unit.

[0091] Specifically, in the general formula 1 above, Q1, Q2 and Q3 can be combined with each other through L.

[0092] More specifically, Q1 and L, Q2 and L, and Q3 may be linked to each other, and at this time, the fusion protein may be one in which Q1, L, Q2, L, and Q3 are linked in the order of general formula 1.

[0093]

[0094] In one embodiment, the linker of the general formula 1 may include, for example, A(EAAAK)n as a repeating unit, wherein n may be 3 to 10, and specifically, n may be 3, 4, 5, 6, 7, 8, 9 or 10, but is not limited thereto.

[0095]

[0096] In one embodiment, the fusion protein may be comprised of amino acids of SEQ ID NO: 5 or SEQ ID NO: 6.

[0097]

[0098] For reference, sequence numbers 1 to 6 used in the present invention are as follows.

[0099] Sequence number and name of the sequence1PD-L1 binding polypeptideMIPGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGF2PD-L1 binding polypeptide(MA)MAIPGGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGF3PD-L1 binding polypeptide(MG)MGIPGGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGF4HSA bindingpolypeptideMIPRGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVLANFFQRRWPGSTNYYIKVRAGDNKYMHLKVFNGPWKFRNTDRGADRVLTGYQVDKNKDDELTGF5XT35_MAMAIPGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKMIPGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKMIPRGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVLAN FFQRRWPGSTNYYIKVRAGDNKYMHLKVFNGPWKFRNTDRGADRVLTGYQVDKNKDDELTGF6XT35_MGMGIPGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKMIPGGLSEAKPATPEIQEIVDKVKPQLEEKTGETYGKLEAVQYKTQVVRRKHFPQWPGTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKMIPRGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVLANFFQRRWPGSTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKMIPRGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVLANFFQRRWPGSTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGFAEAAAKEAAAKEAAAKEAAAKEAAAKMIPRGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVLANFFQRRWPGSTNYYIKVRAGDNKYMHLKVFKSLDLQPREVFQEDLVLTGYQVDKNKDDELTGF

[0100]

[0101] In one embodiment, the fusion protein may be included in a therapeutically effective amount. Specifically, the fusion protein may be present at a concentration of about 1 to 100 mg / mL, a concentration of about 1 to 75 mg / mL, a concentration of about 1 to 50 mg / mL, a concentration of about 1 to 30 mg / mL, a concentration of about 5 to 50 mg / mL, a concentration of about 5 to 30 mg / mL, a concentration of about 10 to 50 mg / mL, a concentration of about 10 to 30 mg / mL, a concentration of about 5 to 25 mg / mL, or a concentration of about 15 to 25 mg / mL, but is not limited thereto. As used herein, the term "about" includes all of ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all of the values ​​in a range equal to or similar to the value following the term "about," but is not limited thereto.

[0102]

[0103] In the present invention, the term “stabilized formulation” may be used interchangeably with “stabilized solution formulation” and “stable solution formulation,” and refers to a formulation that essentially retains the physical and chemical identity and integrity of the fusion protein of the present invention, which is a therapeutically effective ingredient in the formulation, when stored in a solution state. Various analytical techniques for measuring the stability of the fusion protein may be used, such as protein stability assays widely known in the art. Stability can be measured at a selected temperature for a selected time. For rapid testing, the formulation can be stored at a higher or “accelerated” temperature, for example, 25°C for one to five weeks or more, at which point the time stability is measured.

[0104]

[0105] As used herein, the term "pharmaceutically acceptable salt" includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium.

[0106]

[0107] The solution formulation according to the present invention may additionally contain a preservative. The preservative refers to a compound added to a pharmaceutical preparation to act as an antibacterial agent. Examples of such preservatives include, but are not limited to, benzalkonium chloride, benzethonium, chlorhexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, benzoic acid, and the like. These preservatives may be used singly or in any combination of two or more.

[0108]

[0109] The stabilizing agent according to the present invention may be in the form of a pharmaceutical composition. Furthermore, in addition to the ingredients described above, it may contain various pharmaceutically acceptable carriers.

[0110]

[0111] Another aspect of the present invention is a method for preparing a stabilizing formulation of a fusion protein comprising a stabilizer comprising a material providing an anion of the present invention.

[0112] The above terms have been explained previously. Furthermore, it is self-evident that specific examples of each term also apply to this aspect.

[0113]

[0114] Another aspect of the present invention provides a pharmaceutical composition for treating cancer, comprising a fusion protein of the present invention and a pharmaceutically acceptable salt.

[0115] In the present invention, the term "cancer" includes, without limitation, any type of cancer that can be prevented or treated by the fusion protein of the present invention, and examples thereof include, but are not limited to, pancreatic cancer, ovarian cancer, breast cancer, melanoma, liver cancer, cervical cancer, stomach cancer, lung cancer, colon cancer, oral cancer, and bladder cancer. The term "prevention" in the present invention may mean any act of inhibiting or delaying the onset of cancer by administering the composition, and the term "treatment" may mean any act of improving or beneficially changing the symptoms of cancer by administering the composition.

[0116] The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, excipient, or diluent. Such pharmaceutically acceptable carrier, excipient, or diluent may be non-naturally occurring.

[0117] In the present invention, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not stimulate a living organism and does not inhibit the biological activity and properties of the administered compound. In a composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.

[0118] The formulation of the composition of the present invention can be prepared in various ways by mixing it with pharmaceutically acceptable excipients as described above. For example, it can be various oral or parenteral formulations. When formulating, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

[0119] The above pharmaceutical composition may have any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.

[0120] The composition of the present invention is administered in a pharmaceutically effective amount.

[0121] As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined according to factors including the type and severity of the individual, age, sex, type of cancer, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. And it can be administered singly or in multiple doses. It is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects by taking all of the above factors into consideration, and it can be easily determined by those skilled in the art.

[0122] The dosage and frequency of administration of the pharmaceutical composition of the present invention are determined based on the type of drug as the active ingredient, along with various related factors such as the disease to be treated, the route of administration, the patient's age, sex, and weight, and the severity of the disease. Specifically, the composition of the present invention may contain a pharmaceutically effective amount of the fusion protein, but is not limited thereto.

[0123] Including the above fusion protein in a pharmaceutically effective amount means the extent to which the desired pharmacological activity can be achieved due to the fusion protein, and may also mean a pharmaceutically acceptable level where no or minimal toxicity or side effects occur in the administered subject, but is not limited thereto. Such a pharmaceutically effective amount may be determined comprehensively considering the number of administrations, the patient, the formulation, etc.

[0124]

[0125] Although not particularly limited thereto, the pharmaceutical composition of the present invention may contain the fusion protein in an amount of 0.01 to 99% by weight to volume, and may contain a pharmaceutically acceptable excipient in an amount of 1 to 99.99% by weight to volume, based on the total volume of the composition.

[0126]

[0127] The total effective amount of the composition of the present invention can be administered to a patient as a single dose, or can be administered by a fractionated treatment protocol in which multiple doses are administered over a long period of time. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. Specifically, a preferred total dose of the fusion protein of the present invention may be about 0.0001 mg to 500 mg per kg of patient body weight per day, but is not limited thereto. However, the dosage of the conjugate is determined by considering various factors such as the route of administration of the pharmaceutical composition and the number of treatments, as well as the patient's age, weight, health status, sex, severity of the disease, diet, and excretion rate. Therefore, considering this, a person having ordinary skill in the art will be able to determine an appropriate effective dosage according to a specific use of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route, or administration method as long as it exhibits the effects of the present invention.

[0128]

[0129] In another aspect, the present invention provides a method for treating cancer using the fusion protein.

[0130] The fusion protein and cancer are as described above.

[0131] The method for treating cancer may be a method for treating cancer, comprising administering to a subject diagnosed with or suspected of having cancer a pharmaceutical composition further comprising a fusion protein and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is the same as described above. The method for treating cancer may specifically be a method for treating cancer, comprising administering to a subject diagnosed with cancer a composition comprising a fusion protein.

[0132] The above-mentioned subject includes mammals, birds, etc., including cows, pigs, sheep, chickens, dogs, humans, etc., and subjects whose cancer is treated by administration of the composition of the present invention are included without limitation.

[0133] At this time, the composition may be administered singly or multiple times in a pharmaceutically effective amount. At this time, the composition may be administered in the form of a liquid, powder, aerosol, capsule, enteric-coated tablet, or capsule or suppository. Routes of administration include, but are not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. However, since proteins are digested during oral administration, oral compositions must be formulated to coat the active agent or protect it from degradation in the stomach. Furthermore, the pharmaceutical composition may be administered by any device capable of transporting the active agent to target cells.

[0134]

[0135] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention.

[0136]

[0137] Example 1: Preparation of experimental and comparative examples of Affimer-stabilized formulations

[0138]

[0139] 1-1: Experimental Example of Affimer Stabilization Formulation

[0140] The experimental example formulation of the present invention was manufactured based on the following Table 2. Specifically, after preparing a formulation buffer having a target composition, buffer exchange was performed using the XT35 DS stock solution using a centrifugal filter. After placing the DS stock solution in the centrifugal filter, 10 times the target buffer was added, and centrifuged at 3000 rpm x 10 min. After confirming that the volume was reduced by more than 10 times, the solution in the lower layer was discarded, and 10 times the target buffer was added to the upper layer again and centrifuged. The above procedure was repeated 3 or more times to perform buffer exchange.

[0141] However, since surfactants do not filter well at this time, a 10x or 20x stock solution was prepared and spiked into the buffer exchanged solution. Afterwards, the substance of the corresponding formulation was filled into a vial, placed in the stability chamber, and sampled over time for analysis.

[0142] API Concentration (mg / mL) Buffer Stabilizer (mM) Surfactant Osmolarity (mOsm / kg) Example 1 20 pH 6.8 20 mM Histidine buffer K2SO4 270 P188 0.3% 641 Example 2 20 Na2SO4 270 P188 0.3% 627 Example 3 20 Na2SO4 540 P188 0.3% 1121 Example 4 20 NaCl 150 Na2SO4 400 P188 0.3% 1123 Example 5 20 NaCl 300 Na2SO4 270 P188 0.3% 1144 Example 6 20 Malic acid 480 P188 0.3% 1244 Example 7 20 Malic acid 723 P188 0.3%1901Example 820Na2SO4250Malic acid250P188 0.3%1168Example 920NaCl50Na2SO4100Malic acid350P188 0.3%1233Example 1020NaCl80Na2SO4200Malic acid250P188 0.3%1231Example 1110Na2SO4270P188 0.3%611Example 1210Na2SO4540P188 0.3%1105Example 1310Malic acid240P188 0.3%619Example 1410Malic acid480P188 0.3%1211Example 1510NaCl40Na2SO4100Malic acid125P188 0.3%626Example 1625Na2SO4135Malic acid120P188 0.3%618Example 1720NaCl300Tartrate238P188 0.3%1131

[0143]

[0144] 1-2: Comparative Example Preparation of Affimer Stabilized Formulation

[0145] The comparative example formulation of the present invention was manufactured based on the following Table 3. Specifically, after preparing a formulation buffer having a target composition, buffer exchange was performed using the XT35 DS stock solution using a centrifugal filter. After placing the DS stock solution in the centrifugal filter, 10 times the target buffer was added, and centrifuged at 3000 rpm x 10 min. After confirming that the volume was reduced by more than 10 times, the solution in the lower layer was discarded, and 10 times the target buffer was added to the upper layer again and centrifuged. The above procedure was repeated 3 or more times to perform buffer exchange.

[0146] However, since surfactants do not filter well at this time, a 10x or 20x stock solution was prepared and spiked into the buffer exchanged solution. Afterwards, the substance of the corresponding formulation was filled into a vial, placed in the stability chamber, and sampled over time for analysis.

[0147] API Concentration (mg / mL)BufferStabilizer (mM)SurfactantOsmolarity (mOsm / kg)Comparative Example 12020mM HistidinebufferNaCl300 P188 0.3%590Comparative Example 220NaCl600 P188 0.3%1154Comparative Example 320NaCl1000 P188 0.3%1940Comparative Example 420Sodium phosphate320 P188 0.3%636Comparative Example 520Sodium acetate286 P188 0.3%630Comparative Example 620Sodium citrate211 P188 0.3%648Comparative Example 720Sodium succinate217 P188 0.3%623Comparative Example 820NaCl300Beta-CD100P188 0.3%1128Comparative Example 920NaCl 590HA 0.50%P 188 0.3%1183Comparative Example 1020NaCl 500CS-C 2.50%P 188 0.3%1078Comparative Example 1120NaCl 300Maleic acid 262P 188 0.3%1194Comparative Example 1220NaCl 300Propylene glycol 444P 188 0.3%1137

[0148]

[0149] Example 2: Stability verification of Affimer-stabilized formulations

[0150]

[0151] The stability of the experimental and comparative example formulations manufactured in Example 1 was confirmed through SEC (Size Exclusion Chromatography) analysis. SEC is a method of separating a substance based on its size. Through SEC analysis, the impurity profile can be confirmed by distinguishing the monomer (main), the low molecular weight (LMW) decomposition product, and the high molecular weight (HMW) formed by the aggregation of the substance. Specifically, the % of the main product according to the storage temperature condition and time was confirmed through SEC analysis. The results of the experimental example formulation are shown in Table 4, and the results of the comparative example formulation are shown in Table 5.

[0152] SEC Main % Reduction 25C1W25C2W25C3W5C1M5C2M5C3M5C4MExample 1 11.720.526.3 8.1Example 2 10.319.7 2.55.8Example 35.710.4 0.41.1Example 47.213.4 0.82Example 57.613.6 0.92 Example 6 5.7 1 1 1 6.8 0.5 1 9 2.6 3.8 Example 7 3.4 6.6 10.30 1 1 1 3 1 8 Example 8 5.4 1 0.7 1 6.20 41 62 23.1 Example 9 5.7 1 1 1 7 0.41 8 2.4 3.5 Example 10 5.6 1 1 1 6.5 0.41 72 3 3.3 Example 11 9.1 2.2 4.7 6.2 Example 12 4.9 0.7 0.9 1.3 Example 13 9.1 1.3 23 Example 14 6.1 0.9 1.3 1.8 Example 15 8.7 1.1 1 7 2.7 Example 16 1.5 5.8 Example 17 1 1 1 5 23.8 1.7 3.4 5.9

[0153]

[0154] SEC Main % Decrease 25C1W25C2W25C3W5C1M5C2M5C3M5C4MComparative Example 1 12.6 22.7 30.8 6.8 9.8 14.3Comparative Example 2 12.2 22.4 30.7 2.46.49.8 14.5Comparative Example 36.8 12.4 17.7 0.7 2.33.34.7Comparative Example 4 15.9 27.9 36.7 13.7Comparative Example 5 16.5 28.5 35.1 13.8Comparative Example 6 13.5 23.1 29.1 10.6Comparative Example 7 13.2 24.2 30.7 12.1Comparative Example 8 20.3 32.8 1.2 10.4 20.3 Comparative Example 9 14.2 27.92.55.38.7 Comparative Example 1016.3 35.24.68.914.2 Comparative Example 1114.3 26.62.65.79.1 Comparative Example 1217.3 31.12.55.59.2

[0155]

[0156] As a result, it was confirmed that the examples including the stabilizer composed of a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate had an overall superior stability improvement effect compared to the comparative examples. In addition, it was confirmed that the stability effect was superior when the stabilizer of the present invention was included even at various API concentrations, and it was confirmed that the stabilization effect was superior when the stabilizer composed of the substance providing anion of the present invention was included even when some of the stabilizers included in the comparative examples were included.

[0157] Moreover, when treated with a similar level of mole concentration based on a similar osmotic pressure, the stability at 5℃ under long-term storage conditions, in particular, showed excellent stability by significantly reducing the decrease in the Main peak in SEC in the experimental example compared to the comparative example, and the higher the concentration of the stabilizer, the more clearly the stability improvement tendency was shown, showing a magnifying characteristic.

[0158] Through the above results, it was confirmed that sulfate, malate, tartrate, and anion were excellent stabilizers for the affimer. In addition, only the anion type was affected, regardless of the type of cation, and other excipients had minimal stabilizing effects. In addition, when anions with good effects were combined, a similar trend was observed as when only a single excipient was used. In particular, when the concentration of the stabilizer was high, the stabilizing effect was excellent even when some of the NaCl excipient from the comparative example was included.

[0159]

[0160] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.

Claims

1. A fusion protein comprising a structure represented by the following general formula 1; and a stabilizing agent comprising a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate: [General Formula 1] Q1-L-Q2-L-Q3 However, the above Q1 and Q2 include a polynucleotide encoding a PD-L1 binding polypeptide, and Q3 includes a polynucleotide encoding an HSA binding polypeptide, L represents a linker containing A(EAAAK)n as a repeating unit, The above n is an integer from 3 to 10.

2. A stabilizing agent in the first paragraph, wherein the substance providing the anion is at least one selected from the group consisting of ammonium sulfate, potassium sulfate, sodium sulfate, calcium sulfate, magnesium sulfate, malic acid, ammonium malate, sodium malate, calcium malate, potassium malate, magnesium malate, tartaric acid, ammonium tartrate, sodium tartrate, calcium tartrate, potassium tartrate, and magnesium tartrate.

3. A stabilizing agent according to claim 1, wherein the stabilizing agent is present at a concentration of 0.1 mM to 800 mM.

4. A stabilizing agent according to claim 1, wherein the stabilizing agent has increased storage stability compared to a formulation to which a stabilizing agent is added, excluding a substance providing one or more anions selected from the group consisting of sulfate, malate, and tartrate.

5. A stabilizing agent according to claim 1, wherein the stabilizing agent further comprises a surfactant.

6. A stabilizing agent according to claim 5, wherein the surfactant is a nonionic surfactant.

7. A stabilizing agent according to claim 6, wherein the surfactant is polysorbate or poloxamer.

8. A stabilizing agent according to claim 6, wherein the surfactant is polysorbate 80, polysorbate 20, or poloxamer 188.

9. A stabilizing agent according to claim 1, wherein the surfactant is present in a concentration of 0.1 to 2 wt%.

10. A stabilizing formulation according to claim 1, wherein the fusion protein is present at a concentration of 1 to 30 mg / ml.

11. In paragraph 1, A stabilizing agent, wherein the polypeptide encoded by the above Q1 and Q2 has at least 90% identity with the sequence represented by SEQ ID NO:

1.

12. In paragraph 11, A stabilizing agent, wherein the polypeptide encoded by the above Q1 is composed of amino acids of sequence number 2 or sequence number 3.

13. In paragraph 11, A stabilizing agent, wherein the polypeptide encoded by the above Q2 is composed of amino acids of sequence number 1.

14. In paragraph 1, A stabilizing agent, wherein the polypeptide encoded by the above Q3 has at least 90% identity with the sequence represented by SEQ ID NO:

4.

15. In paragraph 14, A stabilizing agent, wherein the polypeptide encoded by the above Q3 is composed of amino acids of sequence number 4.

16. A stabilizing agent according to claim 1, wherein the fusion protein is composed of amino acids of sequence number 5 or sequence number 6.

Citation Information

Patent Citations

  • Improved stabilizer cyanoacrylate formulations

    KR1020080064815A

  • Method and server for providing project marketing strategies based on the degree of fit between users and projects using ai models

    KR102592637B1

  • STABILIZED Fc FUSION PROTEIN SOLUTIONS

    US20220125718A1

  • Serum half-life extended PD-l1 binding polypeptides

    WO2023057946A1